145 related articles for article (PubMed ID: 21386766)
1. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
[TBL] [Abstract][Full Text] [Related]
2. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
[TBL] [Abstract][Full Text] [Related]
3. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
Sheetz MJ; Aiello LP; Davis MD; Danis R; Bek T; Cunha-Vaz J; Shahri N; Berg PH;
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1750-7. PubMed ID: 23404115
[TBL] [Abstract][Full Text] [Related]
4. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
[TBL] [Abstract][Full Text] [Related]
5. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.
Girach A; Aiello LP; Milton RC; Davis MD; Danis RP; Zhi X; Sheetz MJ; Vignati L;
Eye (Lond); 2009 Jan; 23(1):209-14. PubMed ID: 18989348
[TBL] [Abstract][Full Text] [Related]
6. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
[TBL] [Abstract][Full Text] [Related]
7. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
PKC-DRS Study Group
Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
[TBL] [Abstract][Full Text] [Related]
8. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
[TBL] [Abstract][Full Text] [Related]
10. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Sahu AK; Majji AB
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
[No Abstract] [Full Text] [Related]
11. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
PKC-DMES Study Group
Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
[TBL] [Abstract][Full Text] [Related]
12. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
Gardner TW; Larsen M; Girach A; Zhi X;
Acta Ophthalmol; 2009 Nov; 87(7):709-13. PubMed ID: 19817721
[TBL] [Abstract][Full Text] [Related]
13. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
Tuttle KR; McGill JB; Haney DJ; Lin TE; Anderson PW;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):631-6. PubMed ID: 17699475
[TBL] [Abstract][Full Text] [Related]
14. Ruboxistaurin: LY 333531.
Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
[TBL] [Abstract][Full Text] [Related]
15. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
[TBL] [Abstract][Full Text] [Related]
16. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
Brooks B; Delaney-Robinson C; Molyneaux L; Yue DK
J Diabetes Complications; 2008; 22(2):88-95. PubMed ID: 18280438
[TBL] [Abstract][Full Text] [Related]
17. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats.
Wei L; Sun D; Yin Z; Yuan Y; Hwang A; Zhang Y; Si R; Zhang R; Guo W; Cao F; Wang H
Apoptosis; 2010 Apr; 15(4):488-98. PubMed ID: 20044781
[TBL] [Abstract][Full Text] [Related]
18. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
Strøm C; Sander B; Klemp K; Aiello LP; Lund-Andersen H; Larsen M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3855-8. PubMed ID: 16186374
[TBL] [Abstract][Full Text] [Related]
19. Ruboxistaurin for diabetic retinopathy.
Gardner TW; Antonetti DA
Ophthalmology; 2006 Dec; 113(12):2135-6. PubMed ID: 17157131
[No Abstract] [Full Text] [Related]
20. PKC inhibition and diabetic microvascular complications.
Clarke M; Dodson PM
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
